Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06571734 · ClinicalTrials.gov registry record · Phase 2
XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma
A Phase 2 study of Metastatic Leiomyosarcoma and Unresectable Leiomyosarcoma, sponsored by Northwestern University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 1
- Study location
NCT06571734: Recruiting Phase 2 study of Metastatic Leiomyosarcoma and Unresectable Leiomyosarcoma, sponsored by Northwestern University.
NCT06571734 is a Phase 2 study of Metastatic Leiomyosarcoma and Unresectable Leiomyosarcoma that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 29 participants, below the 49-participant average among 4 other Metastatic Leiomyosarcoma trials with a reported enrollment target (41% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06571734, a Phase 2 study of Metastatic Leiomyosarcoma and Unresectable Leiomyosarcoma, is actively recruiting participants, sponsored by Northwestern University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial tests how well zanzalintinib (XL092) works in treating patients with leiomyosarcoma that has spread from where it first started to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). Leiomyosarcomas are a type sarcoma that can occur in any location in the body, such as the uterus or in the abdomen. Current standard treatment for leiomyosarcoma only shows a progression-free survival of 4-6 months. XL092, a tyrosine kinase inhibitor, interferes with cell communication and growth and may prevent tumor growth. Giving XL092 may kill more tumor cells in patients with metastatic or unresectable leiomyosarcoma.
Primary Outcome
PFS will be defined as progressive disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1.other documented clinical or radiographic progression per physician judgment, or death due to disease.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- DRUG Zanzalintinib
- PROCEDURE Echocardiography
- PROCEDURE Multigated Acquisition Scan
Study Locations (1)
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2024-09-19 |
| Est. Completion | 2029-07-01 |
| Phase | Phase 2 |
What NCT06571734 shows while recruiting
NCT06571734 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 49-participant average among 4 other Metastatic Leiomyosarcoma trials with a reported enrollment target (41% lower).
The record links to 2 conditions, with Metastatic Leiomyosarcoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT06571734 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06571734 about?
NCT06571734 is a clinical study titled "XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma". This phase II trial tests how well zanzalintinib (XL092) works in treating patients with leiomyosarcoma that has spread from where it first started to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). Leiomyosarcomas are a type sarcoma that can occur in any l...
What is the current status of trial NCT06571734?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2024-09-19. Estimated completion is 2029-07-01.
What conditions does trial NCT06571734 study?
This clinical trial studies the following conditions: Metastatic Leiomyosarcoma, Unresectable Leiomyosarcoma.
What interventions are being tested in trial NCT06571734?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Zanzalintinib (DRUG), Echocardiography (PROCEDURE), Multigated Acquisition Scan (PROCEDURE).
Who is sponsoring clinical trial NCT06571734?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06571734 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Leiomyosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma
ACTIVE NOT RECRUITING · Phase 2
-
SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma
COMPLETED · Phase 2
-
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
RECRUITING · Phase 1
-
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI